ImmuCell Co. (NASDAQ:ICCC) Sees Significant Drop in Short Interest

ImmuCell Co. (NASDAQ:ICCC) saw a large decline in short interest in September. As of September 15th, there was short interest totalling 8,500 shares, a decline of 54.3% from the August 31st total of 18,600 shares. Based on an average daily trading volume, of 35,800 shares, the days-to-cover ratio is presently 0.2 days. Approximately 0.2% of the shares of the stock are sold short.

Institutional Investors Weigh In On ImmuCell

A hedge fund recently bought a new stake in ImmuCell stock. Mesirow Financial Investment Management Inc. acquired a new stake in ImmuCell Co. (NASDAQ:ICCC) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 12,178 shares of the biotechnology company’s stock, valued at approximately $65,000. Mesirow Financial Investment Management Inc. owned 0.16% of ImmuCell as of its most recent SEC filing. Hedge funds and other institutional investors own 13.47% of the company’s stock.

ImmuCell Price Performance

Shares of ICCC traded down $0.06 during midday trading on Friday, hitting $3.55. The company’s stock had a trading volume of 16,710 shares, compared to its average volume of 18,958. The company has a quick ratio of 0.77, a current ratio of 2.37 and a debt-to-equity ratio of 0.42. ImmuCell has a one year low of $3.34 and a one year high of $5.59. The stock has a market capitalization of $27.73 million, a price-to-earnings ratio of -6.96 and a beta of 0.56. The company’s fifty day simple moving average is $3.79 and its two-hundred day simple moving average is $4.43.

ImmuCell (NASDAQ:ICCC) last released its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter. ImmuCell had a negative return on equity of 16.35% and a negative net margin of 17.44%. The company had revenue of $5.47 million for the quarter.

ImmuCell Company Profile

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.